111<\/sup>In-DOTA-BASS, outperformed the “agonist” agent, OctreoScan, that is widely used in the clinic to image neuroendocrine tumors bearing somatostatin receptors.\n<\/p>\n\n“This is the first proof of principle in humans that labeled peptide antagonists can effectively image tumors. Additional research suggests that we could one day use a different radioactive metal to effectively kill the tumors,” said Dr. Rivier.\n<\/p>\n
\nDr. Reubi, a molecular pathologist, and Dr. Rivier, a chemist, collaborated in the design and selection of nat<\/sup>In-DOTA-BASS for human testing, and Dr. Helmut R. Maecke, a radio chemist, loaded DOTA-BASS with its radioactive marker and tested the compound before use in human. Afterward, the “first in man” study with the radioactive loaded DOTA-BASS was performed at the University Hospital in Freiburgby Drs. Damian Wild, Melpomeni Fani, Martin Behe, Ingo Brink, Helmut R. Maecke, and Wolfgang A. Weber.\n<\/p>\n\nThe genesis of this study goes back to 1973, when a team of Salk researchers, which included Drs. Brazeau, Vale, Burgus, Rivier, and Roger Guillemin, a 1977 Nobel laureate, isolated and characterized somatostatin, a peptide produced by neuroendocrine glands. The scientists found that the normal function of somatostatin is to block the release of growth hormone throughout the body, which includes inhibiting the release of thyroid-stimulating hormone (TSH) from the thyroid.\n<\/p>\n
\nDrs. Rivier, Reubi and their colleagues from Germany showed that 111<\/sup>In-DOTA-BASS bound to a greater number of somatostatin receptors on cancer cells than the agonist OctreoScan, and that it did accumulate in normal tissue (liver and kidney) to a lesser extent.\n<\/p>\n\nThe prototype antagonist therapy has been revamped, and the version studied in the Journal of Nuclear Medicine publication, 111<\/sup>In-DOTA-BASS, detected 25 of 28 metastatic neuroendocrine tumors in the patients, whereas OctreoScan detected only 17.\n<\/p>\n\nIn-DOTA-BASS has been licensed to a pharmaceutical company for clinical trial development, according to Rivier, who adds that other researchers are exploring an antagonist approach for other G-protein coupled receptors that are abundantly expressed on cancer cells.\n<\/p>\n
\nThe study was funded in part by the Swiss National Science Foundation (JCR).\n<\/p>\n
\nAcerca del Instituto Salk de Estudios Biol\u00f3gicos:<\/strong>
\nEl Instituto Salk de Estudios Biol\u00f3gicos es una de las instituciones de investigaci\u00f3n b\u00e1sica m\u00e1s destacadas del mundo, donde un cuerpo docente de prestigio internacional investiga cuestiones fundamentales de las ciencias de la vida en un entorno \u00fanico, colaborativo y creativo. Centrados tanto en el descubrimiento como en la formaci\u00f3n de las futuras generaciones de investigadores, los cient\u00edficos del Salk realizan contribuciones revolucionarias a nuestra comprensi\u00f3n del c\u00e1ncer, el envejecimiento, el Alzheimer, la diabetes y las enfermedades infecciosas mediante el estudio de la neurociencia, la gen\u00e9tica, la biolog\u00eda celular y vegetal, y otras disciplinas relacionadas.\n<\/p>\n\nLos logros del cuerpo docente han sido reconocidos con numerosos galardones, entre los que se incluyen premios Nobel y la pertenencia a la Academia Nacional de Ciencias. Fundado en 1960 por el Dr. Jonas Salk, pionero en la vacuna contra la poliomielitis, el Instituto es una organizaci\u00f3n independiente sin fines de lucro y un hito arquitect\u00f3nico.<\/p>\n
For more information:<\/strong>
\nJournal of Nuclear Medicine<\/em>
\nIssue: Sept 1, 2011 vol. 52 no. 9 1412-1417
\n(Published online Aug. 18, 2011)
\nAuthors: Damian Wild, Melpomeni Fani, Martin Behe, Ingo Brink, Jean E.F. Rivier, Jean Claude Reubi, Helmut R. Maecke, and Wolfgang A. Weber
\nFirst Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible<\/p>","protected":false},"featured_media":0,"template":"","faculty":[110],"disease-research":[],"class_list":["post-2128","disclosure","type-disclosure","status-publish","hentry","faculty-jean-rivier"],"acf":[],"yoast_head":"\nFirst proof in patients of an improved "magic bullet" for cancer detection and radio-therapy - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/es\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First proof in patients of an improved "magic bullet" for cancer detection and radio-therapy - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, CA\u2014Oncologists have long sought a powerful “magic bullet” that can find tumors wherever they hide in the body so that they can be imaged and then destroyed. Until recently scientists accepted the notion that such an agent, an agonist, needed to enter and accumulate in the cancerous cells to act. An international research team has now shown in cancer patients that an investigational agent that sticks onto the surface of tumor cells without triggering internalization, an antagonist, may be safer and even more effective than agonists.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/es\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"628\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\\\/\",\"name\":\"First proof in patients of an improved \\\"magic bullet\\\" for cancer detection and radio-therapy - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"datePublished\":\"2011-09-12T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\\\/#breadcrumb\"},\"inLanguage\":\"es-MX\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First proof in patients of an improved “magic bullet” for cancer detection and radio-therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-MX\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-MX\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First proof in patients of an improved \"magic bullet\" for cancer detection and radio-therapy - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/es\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/","og_locale":"es_MX","og_type":"article","og_title":"First proof in patients of an improved \"magic bullet\" for cancer detection and radio-therapy - Salk Institute for Biological Studies","og_description":"LA JOLLA, CA\u2014Oncologists have long sought a powerful “magic bullet” that can find tumors wherever they hide in the body so that they can be imaged and then destroyed. Until recently scientists accepted the notion that such an agent, an agonist, needed to enter and accumulate in the cancerous cells to act. An international research team has now shown in cancer patients that an investigational agent that sticks onto the surface of tumor cells without triggering internalization, an antagonist, may be safer and even more effective than agonists.","og_url":"https:\/\/www.salk.edu\/es\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/","og_site_name":"Salk Institute for Biological Studies","og_image":[{"width":628,"height":329,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/","url":"https:\/\/www.salk.edu\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/","name":"First proof in patients of an improved \"magic bullet\" for cancer detection and radio-therapy - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"datePublished":"2011-09-12T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/#breadcrumb"},"inLanguage":"es-MX","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/first-proof-in-patients-of-an-improved-magic-bullet-for-cancer-detection-and-radio-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"First proof in patients of an improved “magic bullet” for cancer detection and radio-therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Instituto Salk de Estudios Biol\u00f3gicos","description":"The Power of Science","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-MX"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Instituto Salk de Estudios Biol\u00f3gicos","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"es-MX","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"paper_url":"","journal_title":"","paper_author_list":"","paper_title":"","subhead":"Salk Institute scientists collaborate with scientists of the University of Bern and physicians from the University Hospital of Freiburg (D) on the discovery and clinical testing of agents that "detect" more metastatic neuroendocrine tumors than is current","home_photo":"2011\/515_Rivier_J.jpg","listing_photo":"","line_2":"Salk Institute scientists collaborate with scientists of the University of Bern and physicians from the University Hospital of Freiburg (D) on the discovery and clinical testing of agents that "detect" more metastatic neuroendocrine tumors than is current","line_1":"First proof in patients of an improved "magic bullet" for cancer detection and radio-therapy"},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/2128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":0,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/2128\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/media?parent=2128"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/faculty?post=2128"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disease-research?post=2128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}